Brokers

Brokers Set Expectations for Checkpoint Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:CKPT)


Checkpoint Therapeutics, Inc. (NASDAQ:CKPTGet Rating) – Equities research analysts at B. Riley issued their Q2 2022 earnings per share estimates for shares of Checkpoint Therapeutics in a research note issued to investors on Tuesday, May 17th. B. Riley analyst J. Walsh expects that the company will post earnings per share of ($0.22) for the quarter. B. Riley also issued estimates for Checkpoint Therapeutics’ Q3 2022 earnings at ($0.23) EPS, Q4 2022 earnings at ($0.31) EPS, FY2022 earnings at ($0.98) EPS, FY2023 earnings at ($1.14) EPS, FY2024 earnings at ($0.66) EPS, FY2025 earnings at $0.01 EPS and FY2026 earnings at $1.42 EPS.

Several other brokerages have also recently issued reports on CKPT. HC Wainwright raised their target price on shares of Checkpoint Therapeutics from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, January 25th. LADENBURG THALM/SH SH boosted their target price on shares of Checkpoint Therapeutics from $20.00 to $26.00 in a report on Wednesday, January 26th. Finally, Cantor Fitzgerald boosted their target price on shares of Checkpoint Therapeutics from $16.00 to $20.00 in a report on Wednesday, January 26th.

Shares of CKPT opened at $1.39 on Friday. The company has a market capitalization of $125.92 million, a P/E ratio of -1.64 and a beta of 1.71. The firm has a 50 day moving average of $1.51 and a 200 day moving average of $2.33. Checkpoint Therapeutics has a twelve month low of $0.96 and a twelve month high of $4.64.

Checkpoint Therapeutics (NASDAQ:CKPTGet Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). Checkpoint Therapeutics had a negative net margin of 26,592.46% and a negative return on equity of 173.15%.

Several institutional investors have recently made changes to their positions in the company. Level Four Advisory Services LLC acquired a new position in Checkpoint Therapeutics in the 4th quarter valued at $31,000. Eqis Capital Management Inc. purchased a new stake in shares of Checkpoint Therapeutics in the 1st quarter worth about $33,000. JPMorgan Chase & Co. boosted its position in shares of Checkpoint Therapeutics by 73,468.4% in the 4th quarter. JPMorgan Chase & Co. now owns 13,978 shares of the company’s stock worth $43,000 after buying an additional 13,959 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Checkpoint Therapeutics by 22.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 13,941 shares of the company’s stock valued at $46,000 after acquiring an additional 2,541 shares during the last quarter. Finally, Truist Financial Corp increased its stake in shares of Checkpoint Therapeutics by 29.2% during the 3rd quarter. Truist Financial Corp now owns 14,169 shares of the company’s stock valued at $47,000 after acquiring an additional 3,205 shares during the last quarter. 11.87% of the stock is currently owned by institutional investors and hedge funds.

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 38,197 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, March 10th. The shares were sold at an average price of $1.89, for a total transaction of $72,192.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James F. Oliviero III sold 86,353 shares of the firm’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $1.79, for a total transaction of $154,571.87. Following the completion of the transaction, the chief executive officer now directly owns 2,873,291 shares of the company’s stock, valued at approximately $5,143,190.89. The disclosure for this sale can be found here. Insiders sold 145,808 shares of company stock worth $258,864 in the last quarter. Company insiders own 6.10% of the company’s stock.

About Checkpoint Therapeutics (Get Rating)

Checkpoint Therapeutics, Inc, clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company’s lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

Recommended Stories

Earnings History and Estimates for Checkpoint Therapeutics (NASDAQ:CKPT)



Receive News & Ratings for Checkpoint Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Checkpoint Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.